Nelly Kuklin, PhD, joined Compass Therapeutics as Vice President of Immunology in 2019. She brings over 20 years of drug discovery experience in the biotech and pharmaceutical industries. Prior to Compass, Nelly was a Senior Director of Translational Research at Gemini Therapeutics where she successfully developed and executed a clinical biomarker strategy for Age-related Macular Degeneration. Before that, from 2011-2015, Dr. Kuklin led drug development programs in the area of rare diseases and headed the biomarker department at Alexion Pharmaceuticals. In that role, Nelly developed and directed biomarkers strategies for a large program portfolio from discovery to pivotal clinical trials. Earlier in her career, Nelly advanced through various scientific positions of increasing responsibility at Merck & Co. where she successfully led oncology and vaccine programs, including a program addressing Staphylococcus infection, the development of Human Papilloma Virus vaccine (Gardasil), and the development of an IgF1R monoclonal antibody from discovery to clinical trials. As a department head, she built and managed teams of more than 17 scientists and technical personnel.
Nelly holds a PhD in immunology from the University of Tennessee and performed post-doctoral training in immunology at Stanford University. She is an author of over 36 peer reviewed publications and patents.